TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...

TScan Therapeutics (TCRX) has been able to report positive results from its phase 1 multi-arm study for the treatment of patients with several types of hematological malignancies such as acute myeloid ...

Wall Street expects a year-over-year increase in earnings on lower revenues when TScan Therapeutics, Inc. (TCRX) reports results for the quarter ended March 2024. While this widely-known consensus ...